PMC:7696151 / 1765-2156
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 52 | 51-58 | Chemical | denotes | quinine | MESH:D011803 |
| 53 | 107-135 | Disease | denotes | systemic lupus erythematosus | MESH:D008180 |
| 58 | 169-176 | Chemical | denotes | quinine | MESH:D011803 |
| 61 | 185-192 | Disease | denotes | malaria | MESH:D008288 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T3 | 107-135 | Phenotype | denotes | systemic lupus erythematosus | http://purl.obolibrary.org/obo/HP_0002725 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T17 | 47-144 | Sentence | denotes | The quinine soon began to be also used for the treatment of systemic lupus erythematosus [1,2,3]. |
| T18 | 145-276 | Sentence | denotes | The increasing need for quinine, due to malaria diffusion, led the pharmaceutical industry to the creation of a synthetic molecule. |
| T19 | 277-340 | Sentence | denotes | In 1934 Johann (Hans) Andersag and co-workers at the Bayer I.G. |